Investigation of the Relationship between CMYC Gene Polymorphisms and Glioma Susceptibility in Chinese Children

Figures & data

Table 1. Genotype frequencies of CMYC polymorphisms in cases and controls.

Model	Genotype	Control (n, %)	Case (n, %)	OR^a(95%CI)	p Value^a
rs4645943 HWE: p = 0.528
Co-dominant	CC	120 (48.4)	96 (50.5)	1.00
Heterozygote	CT	108 (43.6)	82 (43.2)	0.95 (0.64–1.41)	0.794
Homozygote	TT	20 (8.1)	12 (6.3)	0.75 (0.35–1.61)	0.461
Dominant	CC	120 (48.4)	96 (50.5)	1.00
Recessive	CT + TT	128 (51.6)	94 (49.5)	0.92 (0.63–1.34)	0.657
	CC + CT	228 (91.9)	178 (93.7)	1.00
	TT	20 (8.1)	12 (6.3)	0.77 (0.37–1.61)	0.486
Overdominant	CC + TT	140 (56.5)	108 (56.8)	1.00
	CT	108 (43.6)	82 (43.2)	0.98 (0.67–1.44)	0.935
Allele	C	348 (70.2)	274 (72.1)	1.00
	T	148 (29.8)	106 (27.9)	0.91 (0.68–1.22)	0.530
rs2070583 HWE: p = 0.678
Co-dominant	AA	177 (71.4)	139 (73.2)	1.00
Heterozygote	AG	64 (25.8)	48 (25.3)	0.96 (0.62–1.48)	0.836
Homozygote	GG	7 (2.8)	3 (1.6)	0.55 (0.14–2.15)	0.386
Dominant	AA	177 (71.4)	139 (73.2)	1.00
	AG + GG	71 (28.6)	51 (26.8)	0.92 (0.60–1.40)	0.679
Recessive	AA + AG	241 (97.2)	187 (98.4)	1.00
	GG	7 (2.8)	3 (1.6)	0.55 (0.14–2.17)	0.394
Overdominant	AA + GG	184 (74.2)	142 (74.7)	1.00
	AG	64 (25.8)	48 (25.3)	0.97 (0.63–1.50)	0.897
Allele	A	418 (84.3)	326 (85.8)	1.00
	G	78 (15.7)	54 (14.2)	0.89 (0.61–1.29)	0.535

HWE: Hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval.

Table 2. Association between CMYC gene polymorphisms and glioma susceptibility in Chinese children.

Genotype	Cases (N = 190)	Controls (N = 248)	P^a	Crude OR (95% CI)	P	Adjusted OR (95% CI)^b	P^b
rs4645943 C>T (HWE = 0.528)
CC	96 (50.53)	120 (48.39)		1.00		1.00
CT	82 (43.16)	108 (43.55)		0.95 (0.64–1.41)	0.794	0.92 (0.62–1.37)	0.688
TT	12 (6.32)	20 (8.06)		0.75 (0.35–1.64)	0.461	0.76 (0.35–1.64)	0.481
Additive			0.487	0.90 (0.66–1.22)	0.487	0.90 (0.66–1.22)	0.486
Dominant	94 (49.47)	128 (51.61)	0.657	0.92 (0.63–1.34)	0.657	0.91 (0.62–1.33)	0.608
Recessive	178 (93.68)	228 (91.94)	0.486	0.77 (0.37–1.61)	0.487	0.80 (0.38–1.69)	0.555
rs2070583 A>G (HWE = 0.678)
AA	139 (73.16)	177 (71.37)		1.00		1.00
AG	48 (25.26)	64 (25.81)		0.96 (0.62–1.48)	0.836	0.98 (0.63–1.52)	0.922
GG	3 (1.58)	7 (2.82)		0.55 (0.14–2.15)	0.386	0.62 (0.16–2.46)	0.495
Additive			0.514	0.88 (0.61–1.29)	0.514	0.91 (0.62–1.33)	0.631
Dominant	51 (26.84)	71 (28.63)	0.679	0.92 (0.60–1.40)	0.679	0.94 (0.62–1.44)	0.783
Recessive	187 (98.42)	241 (97.18)	0.388	0.55 (0.14–2.17)	0.394	0.61 (0.15–2.40)	0.477
Combined effect of protective genotypes^c
0	93 (48.95)	119 (47.98)	0.594	1.00		1.00
1	49 (25.79)	59 (23.79)		1.06 (0.67–1.69)	0.798	1.00 (0.62–1.61)	0.991
2	48 (25.26)	70 (28.23)		0.88 (0.56–1.39)	0.575	0.94 (0.74–1.18)	0.571
0–1	142 (74.74)	178 (71.77)		1.00		1.00
2	48 (25.26)	70 (28.23)	0.489	0.86 (0.56–1.32)	0.489	0.89 (0.58–1.36)	0.581

OR; odds ratio; CI: confidence interval; HWE: Hardy-Weinberg equilibrium.

^aχ² test for genotype distributions between glioma patients and cancer-free controls.

^bAdjusted for age and gender.

^cProtective genotypes were carriers with rs4645943 CT/TT, rs2070583 AG/GG genotypes.

Table 3. Stratification analysis of risk genotypes with glioma susceptibility.

Variables	rs4645943		AOR (95% CI)^a	^ap Value	rs2070583		AOR (95% CI)^a	^ap Value	Protective genotypes		AOR (95% CI)^a	^ap Value
	(cases/controls)				(cases/controls)				(cases/controls)
	CC	CT/TT			AA	AG/GG			0–2	3
Age, month
<60	50/64	47/62	0.99 (0.58–1.68)	0.957	69/91	28/35	1.08 (0.60–1.94)	0.810	71/92	26/34	1.01 (0.56–1.85)	0.967
≥60	46/56	47/66	0.86 (0.49–1.53)	0.616	70/86	23/36	0.98 (0.47–1.73)	0.755	71/86	22/36	0.88 (0.46–1.70)	0.705
Gender
Females	42/55	46/49	1.15 (0.65–2.05)	0.637	68/77	20/27	0.82 (0.42–1.60)	0.562	70/77	18/27	0.71 (0.36–1.40)	0.318
Males	54/65	48/79	0.75 (0.45–1.25)	0.265	71/100	31/44	1.04 (0.59–1.80)	0.904	72/101	30/43	1.03 (0.59–1.81)	0.919
Subtypes
Astrocytic tumors	70/120	66/128	0.86 (0.56–1.32)	0.492	103/177	33/71	0.83 (0.51–1.36)	0.464	103/178	33/70	0.85 (0.52–1.38)	0.503
Ependymoma	20/120	13/128	0.69 (0.32–1.47)	0.333	25/177	8/71	0.83 (0.35–1.95)	0.668	27/178	6/70	0.60 (0.24–1.53)	0.283
Neuronal and mixed	5/120	9/128	1.65 (0.53–5.13)	0.384	7/177	7/71	2.36 (0.79–7.05)	0.123	7/178	7/70	2.44 (0.82–7.29)	0.109
Embryonal tumors	1/120	6/128	3.48 (0.38–31.85)	0.269	4/177	3/71	1.73 (0.33–9.01)	0.518	5/178	2/70	0.94 (0.16–5.69)	0.945
Clinical stages
I	53/120	57/128	1.00 (0.63–1.57)	0.985	79/177	31/71	1.02 (0.62–1.68)	0.949	79/178	31/70	1.03 (0.63–1.71)	0.898
II	26/120	14/128	0.54 (0.26–1.09)	0.085	31/177	7/71	0.56 (0.23–1.33)	0.186	31/178	7/70	0.57 (0.24–1.35)	0.202
III	9/120	8/128	0.93 (0.34–2.53)	0.878	11/177	6/71	1.39 (0.49–3.94)	0.535	13/178	4/70	0.81 (0.25–2.61)	0.727
IV	10/120	15/128	1.20 (0.50–2.89)	0.690	18/177	7/71	0.99 (0.38–2.60)	0.980	19/178	6/70	0.85 (0.31–2.34)	0.757
I + II	77/120	71/128	0.85 (0.57–1.29)	0.449	110/177	38/71	0.88 (0.55–1.40)	0.588	110/178	38/70	0.90 (0.56–1.42)	0.641
III + IV	19/120	23/128	1.06 (0.54–2.07)	0.868	29/177	13/71	1.15 (0.56–2.36)	0.706	32/178	10/70	0.82 (0.38–1.77)	0.605

AOR: adjusted odds ratio; CI: confidence interval.

^aAdjusted for age and gender, omitting the corresponding stratify factor.

Table 4. The frequency of inferred haplotypes of CMYC gene based on observed genotypes and their association with the risk of Glioma.

Genotypes		Cases	Controls	OR (95% CI)	p Value	AOR (95% CI)^a	^ap Value
rs4645943	rs2070583	(n = 190)	(n = 248)
CC	AA	93 (48.95)	119 (47.98)	1.00		1.00
CC	AG	3 (1.58)	0 (0.00)	NA	NA	NA	NA
CT	AA	44 (23.16)	52 (20.97)	1.08 (0.67–1.76)	0.748	0.01 (0.62–1.67)	0.955
CT	AG	38 (20.00)	55 (22.18)	0.88 (0.54–1.45)	0.625	0.88 (0.53–1.45)	0.610
CT	GG	0 (0.00)	1 (0.00)	NA	NA	NA	NA
TT	AA	2 (0.01)	6 (0.02)	0.427 (0.08–2.16)	0.304	0.398 (0.08–2.10)	0.277
TT	AG	7 (0.04)	8 (0.03)	1.12 (0.39–3.20)	0.833	1.13 (0.39–3.29)	0.818
TT	GG	3 (0.02)	6 (0.02)	0.64 (0.12–2.63)	0.535	0.68 (0.16–2.84)	0.597

^aObtained in logistic regression models with adjustment for age and gender.

Data availability statement

All the data used to support the findings of this study are available from the corresponding author upon request.